References
Duffy D, Rader DJ: Emerging therapies targeting highdensity lipoprotein metabolism and reverse cholesterol transport. Circulation 2006, 113:1140–1150.
Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410–418.
Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.
Barter PJ, Brewer HB Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160–167.
Okamoto H, Yonemori F, Wakitani K, et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203–207.
Yvan-Charvet L, Matsuura F, Wang N, et al.: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007, 27:1132–1138.
Oram JF, Heinecke JW: ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005, 85:1343–1372.
Chait A, Han CY, Oram JF, Heinecke JW: Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005, 46:389–403.
Shao B, Oda MN, Oram JF, Heinecke JW: Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol 2006, 21:322–328.
Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032–13037.
Vaisar T, Pennathur S, Green PS, et al.: Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007, 117:746–756.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oram, J.F., Heinecke, J.W. When good cholesterol turns bad: The evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Curr Atheroscler Rep 9, 425–427 (2007). https://doi.org/10.1007/s11883-007-0055-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11883-007-0055-y